Serotonin Syndrome Dr Swapnil Pawar
Diuretics Dr Swapnil Pawar
IV Thyroxine in Brain Dead Organ Donors Dr Swapnil Pawar
NIV in COVID-19
Dr Swapnil Pawar
Current Guidelines –
Available Evidence –
Does CPAP or HFNO, compared with conventional oxygen therapy, reduce the need for tracheal intubation or mortality within 30 days in COVID-19-related acute respiratory failure?
The RECOVERY-RS trial was a 3-group, randomized clinical trial. The trial was conducted across 48 acute care hospitals in the UK and Jersey.
In effect, RECOVERY-RS represents two separate trials that compare CPAP and HFNO with a common control group of conventional oxygen therapy.
Allowed the hospital site to randomize patients to (1) CPAP, HFNO, or conventional oxygen therapy (on a 1:1:1 basis) or (2) a single intervention (CPAP or HFNO) or conventional oxygen therapy (on a 1:1 basis) depending on availability
Randomization was stratified by hospital site, sex, and age
Adult hospitalized patients (aged ≥18 years) with known or suspected COVID-19 with acute hypoxemic respiratory failure were eligible. Acute hypoxemic respiratory failure was defined as oxygen saturation of 94% with a FiO2 of 0.40 or more. The patients included were planned to undergo full support including invasive ventilation if they deteriorate.
Immediate intubation required
Only for end-of-life care
Conventional oxygen therapy was through a standard face mask or nasal cannula.
CPAP group had no positive inspiratory pressure. The choice of device choice, set up and titration of support was based on individual policies or clinician judgement. Intubation was based on clinician judgment. The crossover was defined as the alternate modality (CPAP or HFNO) for longer than 6 hours.
Sample size calculated based on a 15% incidence of the composite primary outcome of intubation or mortality within 30 d; assuming 5% reduction, power of 90%; 2-sided significance level of .05. Inverse probability weighting was carried out as a correction for crossover
A thousand patients were planned in each group; later the total sample size increased to 4002 due to uncertainty regarding event rates and the changing incidence of Covid-19
Analysis based on the intervention they were randomized to.
The trial was stopped early due to declining in Covid patients and a lack of continued funding after the recruitment of 1278 patients as against the projected 4002 patients.
Composite primary outcome
Length of stay in the ICU
Length of stay in the hospital
An inverse probability weighting analysis that accounted for crossovers to the other treatment groups resulted in similar estimates
Post Hoc outcomes
The primary composite outcome CPAP vs. HFNC: 34.6% (91/263) vs. 44.3% (136/307) P = .02
Significantly in favour of CPAP
ICU, hospital mortality: no difference
ICU, hospital LOS: no difference
Adjusted analyses and the inverse probability weighting analysis were consistent with the primary analysis not statistically significant
Age, sex, BMI, race, time of onset to randomization, FiO2 less than 0.6 vs. more
For HFNO, FiO2 >0.6 benefited compared to oxygen
Four of the serious adverse events were classified as probably or possibly linked to the trial intervention and all of these events occurred in the CPAP group (1 patient with surgical emphysema and pneumomediastinum, 2 patients with pneumothorax and pneumomediastinum, and 1 patient with vomiting requiring emergency tracheal intubation)
Dr Swapnil Pawar February 22, 2022
play_arrow Long Term Outcomes in COVID-19 Dr Swapnil Pawar Clinical Outcomes Among Patients With 1-Year Survival Following Intensive Care Unit Treatment for COVID-19 Heesakkers H, van der Hoeven JG, Corsten […]